Kyverna Therapeutics Enters Manufacturing Supply Agreement for miv-cel

What Happened
Kyverna Therapeutics, Inc. (KYTX) announced on July 27, 2026 that it entered a Clinical and Commercial Supply Agreement with ElevateBio Basecamp, Inc. on July 23, 2026. The agreement replaces a prior Development and Manufacturing Services Agreement that began on July 22, 2023, and covers development and manufacturing services for clinical and commercial supply of the company’s lead product candidate, mivocabtagene autoleucel (“miv‑cel”). Kyverna filed the arrangement in an 8‑K and furnished a joint press release with ElevateBio.

Key Details

• Parties & product: Kyverna Therapeutics and ElevateBio Basecamp, Inc.; covers manufacturing of mivocabtagene autoleucel (miv‑cel).
• Agreement date & term: Agreement dated July 23, 2026; initial term of five years with automatic one‑year renewals unless timely terminated.
• Purchase & pricing terms: Kyverna agreed to minimum order commitments in certain calendar years and/or after regulatory approval; pricing and service fees are set in statements of work and are subject to an annual inflation adjustment tied to the Producer Price Index for Pharmaceutical Preparation Manufacturing (capped at a maximum percentage).
• Disclosure: Kyverna will file the full agreement with its Q3 2026 Form 10‑Q and intends to seek confidential treatment for certain terms; a joint press release was issued July 27, 2026.

Why It Matters
This agreement secures a multi‑year manufacturing partner for Kyverna’s lead cell therapy candidate, which is a key operational step toward clinical supply and potential commercialization. The minimum purchase commitments and inflation‑linked pricing introduce contractual obligations and cost exposure that investors should watch as the company advances regulatory milestones (including any FDA approval). The five‑year initial term with auto‑renewal provides stability in supply planning, while Kyverna’s request for confidential treatment means some commercial details will remain undisclosed until filed.